Bharat Biotech ramps up Covaxin production capacity to 700 mn doses per annum

Bharat Biotech ramps up Covaxin production capacity to 700 mn doses per annum Inactivated vaccines, while highly safe, are extremely complex and expensive to manufacture, resulting in lower yields when compared to live virus vaccines, it noted. https://ift.tt/eA8V8J